NDAORALTABLET
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
21
Data completeness
4/8 — Partial
Schedule 5
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REYVOW (lasmiditan) is an oral small-molecule tablet approved by the FDA in October 2019 for the acute treatment of migraine. As a 5-HT1F receptor agonist, lasmiditan represents a novel mechanism distinct from traditional triptans, offering an alternative for patients who cannot tolerate or do not respond to existing migraine therapies. The product is currently in its peak lifecycle stage, marketed by Eli Lilly and Company.
$0.0BPart D
14.2 years to LOEMechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
A Study to Compare Two Different Formulations of Lasmiditan in Healthy Participants
Started May 2021
47 enrolled
Healthy
A Study of Lasmiditan in Healthy Volunteers
Started Feb 2021
97 enrolled
Healthy
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Started Jun 2020
566 enrolled
Migraine
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Started Jun 2020
851 enrolled
Migraine
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean
Started Mar 2020
294 enrolled
Acute Migraine
Worked on REYVOW at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.